Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

The Mini Nutritional Assessment was viable for assessing nutritional status and predicting mortality outcomes in patients ...

The biotech halted dosing in two study arms after finding instances of pericardial effusion in testing of its drug, which analysts have viewed as a potential threat to Merck’s Winrevair.

Keros (KROS) stock plunged 76% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug ...

Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...